Perifosine (KRX-0401)

Catalog No.S1037 Synonyms: NSC639966

Perifosine (KRX-0401) Chemical Structure

Molecular Weight(MW): 461.66

Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 88 Publications

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.
Targets
Akt [1]
(MM.1S cells)
4.7 μM
In vitro

Perifosine develops anti-proliferative properties with IC50 of 0.6-8.9 μM in immortalized keratinocytes (HaCaT), and head and neck squamous carcinoma cells. [1] Perifosine strongly reduces phosphorylation levels of Akt and extracellular signal-regulated kinase (Erk) 1/2, induces cell cycle arrest in G1 and G2, and causes dose-dependent growth inhibition of mouse glial progenitors. [2] Perifosine (10 μM) completely inhibits the phosphorylation of Akt in MM.1S cells. [3] A recent study demonstrates Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of Akt phosphorylation. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
T24 BC  NWDFbo1TTnWwY4Tpc44hSXO|YYm= Mn30NE42NzFxMj61JO69VQ>? M2rubFMhcA>? MVPy[YR2[2W|IITo[UBj[XOjbDDDRkB1gXKxc3nu[UBxcG:|cHjvdplt[XSrb36gcIV3\Wy|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NX:xXFNDOjZyOUe4O|M>
T24 BC  MnjER4VtdCCYaXHibYxqfHliQYPzZZk> NGrhRnAxNjVxMT:yMlUh|ryP NH7Te3AzPCCq MmrW[Y5p[W6lZYOgd49z[W[nbnniMYlv\HWlZXSgZ4VtdCC4aXHibYxqfHliZHXjdoVie2V? M3;H[VI3ODl5OEez
T24 BC  NEHRdGdCeG:ydH;zbZMhSXO|c3H5 Mnm0Nk42KM7:TR?= M1jUR|I1KGh? NFrKS2R{\W6|aYTpfoV{KEKFIHPlcIx{KHSxIIPvdoFn\W6rYj3pcoR2[2WmIHHwc5B1d3SrY9Mg Mm\2NlYxQTd6N{O=
HepG2 NF7YTo9HfW6ldHnvckBCe3OjeR?= NICyZoozOMLizszN Mn7VNlTDqGh? NIr4WXlxem:mdXPld{BidiCrboTlcpNmKGO7dH;wcIF{dWmlII\hZ5VwdGm8YYTpc44h[2:{cnXzdI9v\GmwZzD0c{BiKG6xdHHicIUh\GmuYYTheIlwdiCxZjD0bIUhTVJiY3nzeIVzdnN? NELRRmgzPTl|NEKzNi=>
U-87 MG  MVfGeY5kfGmxbjDBd5NigQ>? M3T4O|IxyqEQvF2= NIXIcVAzPMLiaB?= MWTpcoNz\WG|ZYOg[I92[mynLX3lcYJz[W6nIHLveY5lKHO2coXjeJVz\XN? MXSyOVk{PDJ|Mh?=
HepG2 M1LqdmZ2dmO2aX;uJGF{e2G7 M37hVVIxyqEQvF2= M4jtdFYwOjRiaB?= NIf2[lJqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjDMR|MuUUliY3;0doVifGWmIIfpeIghS1F? MWCyOVk{PDJ|Mh?=
U-87 MG  M3jn[WZ2dmO2aX;uJGF{e2G7 M2rEcVIxyqEQvF2= MV:2M|I1KGh? NYLvWYhTcW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gUGM{NUmLIHPveJJm[XSnZDD3bZRpKEOT MYmyOVk{PDJ|Mh?=
HepG2 NVjGPXVHTnWwY4Tpc44hSXO|YYm= MmLqNlDDqM7:TR?= MV62M|I1KGh? NGrWUpNl\WO{ZXHz[ZMhVEN|LVnJJIRm\3KjZHH0bY9vyqCocn;tJFYhcA>? M1zJbFI2QTN2MkOy
U-87 MG  NHHWXodHfW6ldHnvckBCe3OjeR?= NXHxSo1UOjEEoN88US=> NIHaTo83NzJ2IHi= NFXUUHhqdmO{ZXHz[ZMhfGinIHH1eI9xcGGpaXOg[ox2gCBiYYSgOkBpKHeqaXzlJIlvcGmkaYTzJJRpcXNiZnz1fEBifCB{NHi= MlnZNlU6OzR{M{K=
HepG2 MlrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX6yNE81OCEQvF2= NFfFboEzPC92ODDo NIHvdmtqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MkLqNlU6OzR{M{K=
U-87 MG  Mn7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWK5fGpUOjBxNECg{txO NWrQPXRPOjRxNEigbC=> NGPa[GlqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MXKyOVk{PDJ|Mh?=
A549 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVKwMlMuOTBizszN MXOyOE84OiCq NHTqbo9qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= Mom1NlU3QTd6OUm=
H460 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW[wMlMuOTBizszN MVOyOE84OiCq NV2wd5NUcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MmHYNlU3QTd6OUm=
A549 NWnK[5YzSXCxcITvd4l{KEG|c4PhfS=> M33SNlEwOyEQvF2= MUC0PEBp M3TmTYlv\HWlZYOgZZBweHSxc3nz Mo\jNlU3QTd6OUm=
H460 NYG0U4F3SXCxcITvd4l{KEG|c4PhfS=> M{i1NFEwOyEQvF2= NHKwUnM1QCCq MnLZbY5lfWOnczDhdI9xfG:|aYO= MYCyOVY6Pzh7OR?=
A549 MYfGeY5kfGmxbjDBd5NigQ>? MXOzJO69VQ>? NUnLZVdxQCCq MoDnZoxw[2u|IFHLWEBi[3SrdnH0bY9v M2nyflI2Pjl5OEm5
H460 M2rGeGZ2dmO2aX;uJGF{e2G7 NEGybIk{KM7:TR?= MkiwPEBp MX7icI9kc3NiQVvUJIFkfGm4YYTpc44> NYjrN3U{OjV4OUe4PVk>
A549 NIDaO3JHfW6ldHnvckBCe3OjeR?= M{TPeFMh|ryP NXLlXWRiQCCq MYjicI9kc3NibWTPVmMyNCCjbnSgSXJMNU2DUFugZYN1cX[jdHnvckBkd22kaX7l[EB4cXSqIF3FT{0yPjJ? MknnNlU3QTd6OUm=
H460 M{nWZWZ2dmO2aX;uJGF{e2G7 MYezJO69VQ>? NVrjfmdmQCCq MljUZoxw[2u|IH3UU3JEOSxiYX7kJGVTUy2PQWDLJIFkfGm4YYTpc44h[2:vYnnu[YQhf2m2aDDNSWsuOTZ{ M1PhVFI2Pjl5OEm5
RMG1 MUXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MnjwNU0{OCEQvF2= Mmr2O|IhcA>? NF30[GZl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MVuyOVUyQTF2OB?=
RMG2 MljuR4VtdCCYaXHibYxqfHliQYPzZZk> M4PldlEuOzBizszN MoC0O|IhcA>? MUXk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MUeyOVUyQTF2OB?=
KOC7C NGrlbZRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NU\Xc2d7OS1|MDFOwG0> NWfVO|JLPzJiaB?= MW\k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MXeyOVUyQTF2OB?=
HAC2 M4PvcWNmdGxiVnnhZoltcXS7IFHzd4F6 NF;4ZpoyNTNyIN88US=> M33scVczKGh? NHzqcnZl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NX\aWHdzOjV3MUmxOFg>
RMG2 NFXnbHNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MX2xMVMxKM7:TR?= Mmr4OFghcA>? NYjreYdq\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy M{fOZlI2PTF7MUS4
OVISE M3TVOGNmdGxiVnnhZoltcXS7IFHzd4F6 NUO3PW1GOS1|MDFOwG0> M1rEe|Q5KGh? Mkez[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NVHYfoZFOjV3MUmxOFg>
SKOV3 NVLsc|lpS2WubDDWbYFjcWyrdImgRZN{[Xl? MlexNU0{OCEQvF2= MYi0PEBp MmDK[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MWmyOVUyQTF2OB?=
A2780 MXXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M1\sNVEuOzBizszN M37jPFQ5KGh? MljR[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MoToNlU2OTlzNEi=
RMG1 NIj2d3ZCeG:ydH;zbZMhSXO|c3H5 Ml\ZN|Ah|ryP MWmyOEBp NWPmcWw{cW6mdXPld{BieG:ydH;zbZM> M3m4OFI2PTF7MUS4
RMG2 NEPG[5NCeG:ydH;zbZMhSXO|c3H5 NHvaS3M{OCEQvF2= MV:yOEBp NVXUZop7cW6mdXPld{BieG:ydH;zbZM> MXSyOVUyQTF2OB?=
HCC1806 NVv5TFUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYmwMVExKM7:TR?= MUm0PEBp MkfzSWM2OD1{Lki05qCKyrIkgJmwMlA4KM7:TR?= MmnxNlUzQTN3N{[=
MDA-MB-231  MnzDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljjNE0yOCEQvF2= M1[5UlQ5KGh? MoW3SWM2OD1zLkGz5qCKyrIkgJmwMlA4KM7:TR?= M4XFXVI2Ojl|NUe2
GL-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY[wMlHjiJNzMEFihKnPxE1? NWHBWndWPDhiaB?= M1fGd2lEPTB;OT65NUDPxE1? MYOyOFg5OTVyOB?=
CLBL-1 NU\PN2l3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWSwMlHjiJNzMEFihKnPxE1? Mkm5OFghcA>? MV7JR|UxRTN|LkCg{txO MnfONlQ5QDF3MEi=
UL-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGL6WFIxNjIkgKOxNFDjiIoQvF2= NFSwRY41QCCq MmXoTWM2OD15LkCxJO69VQ>? MWSyOFg5OTVyOB?=
Ema NYjFNZRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkm2NE4y6oDVMUCw5qCK|ryP MV:0PEBp MWLJR|UxRTV6Lkeg{txO MVWyOFg5OTVyOB?=
PANC-1 MnLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHlNE0zPSEQvF2= MlO2O|IhcA>? M1G5NIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz Moq0NlQ2OTl5NUG=
MIA NV;hfY11T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHkbHYxNTJ3IN88US=> NV7kOGl[PzJiaB?= MV3pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> M{e0cVI1PTF7N{Wx
AsPC-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIK2eWwxNTJ3IN88US=> M{TIVFczKGh? M1fZ[4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NGXvVpEzPDVzOUe1NS=>
PANC-1 NUK4NJpXTnWwY4Tpc44hSXO|YYm= MnXsNE42KM7:TR?= NWXrNY9IOjRiaB?= M2nGeolvcGmkaYTzJGFsfCxiU{\LNUwh[W6mIFXyb|EwOiCyaH;zdIhwenmuYYTpc47DqA>? MnPLNlQ2OTl5NUG=
MIA Mnn4SpVv[3Srb36gRZN{[Xl? MlXQNE42KM7:TR?= M1XKSVI1KGh? MW\pcohq[mm2czDBb5QtKFN4S{GsJIFv\CCHcnuxM|IheGixc4Doc5J6dGG2aX;uxsA> NWnFTINQOjR3MUm3OVE>
AsPC-1 M{D3XWZ2dmO2aX;uJGF{e2G7 MlSwNE42KM7:TR?= MVuyOEBp MoTtbY5pcWKrdIOgRYt1NCCVNluxMEBidmRiRYLrNU8zKHCqb4PwbI9zgWyjdHnvcuKh NGLCPXIzPDVzOUe1NS=>
U87MG NEDK[W5E\WyuIG\pZYJqdGm2eTDBd5NigQ>? NEmzU2wxNTJ3IN88US=> MojENlQuQTZiaB?= MmLy[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy MlnMNlQxPjV3MkK=
SGC7901  NF\FPJlHfW6ldHnvckBCe3OjeR?= M2XWSVAvPzVxMUFCpO69VQ>? MnriOFghcA>? MWHk[YNz\WG|ZYOgdE1Cc3RiKGPldkA1PzNrLDDwMWdUUzQQsjCoV4VzKDlrLDDhcoQhSy2PWVOgcIV3\Wy|wrC= NEjOeGszOzlzMkK0Oi=>
MGC803  M1HYSmZ2dmO2aX;uJGF{e2G7 NUPyR3d7OC55NT:xNOKh|ryP M1LieFQ5yqCq NWDkSmRM\GWlcnXhd4V{KHBvQXv0JEhU\XJiNEezLUwheC2JU1uz{tIhMFOncjC5LUwh[W6mIFOtUXlEKGyndnXsd:Kh NFfXbG0zOzlzMkK0Oi=>
TykNu MlnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3qbZpKSzVyPUOuOUDPxE1? M2P1NlI{QDd5MEGy
TykNuR NYG1R2NiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTwfWI6UUN3ME21MlUh|ryP NX3Henc4OjN6N{ewNVI>
M41 NVjNVJM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTJ2Lkeg{txO MXKyN|g4PzBzMh?=
M41R NX3KUIFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PXeWlEPTB;MUmuPEDPxE1? MkLrNlM5PzdyMUK=
OVCAR8 NGPqOG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTNzLkGg{txO NYPpW2lKOjN6N{ewNVI>
HeyA8 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1m4b2lEPTB;MkSuN{DPxE1? NVv6WWlUOjN6N{ewNVI>
A2780CP MnuwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fLXmlEPTB;Nz62JO69VQ>? MV6yN|g4PzBzMh?=
OVCAR5 MofkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nyeGlEPTB;Nj63JO69VQ>? NX;xTmZXOjN6N{ewNVI>
A2780S NVLRZolCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nzbmlEPTB;MUSuOUDPxE1? M1P3eVI{QDd5MEGy
MCAS NGW5eYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHPS5JKUUN3ME2xNk42KM7:TR?= MofYNlM5PzdyMUK=
NCI-H727 NHX3WJdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M3LqR|AuOTByIN88US=> MViyOE84OiCq NHHWTWRl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> MkLKNlI1QTl2M{e=
GOT1 MoPQR4VtdCCYaXHibYxqfHliQYPzZZk> MViwMVExOCEQvF2= NEfjepQzPC95MjDo NWrJTndy\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGKxdHig[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz NGO5NGczOjR7OUSzOy=>
BON1 NEnBTVJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M3:2WlAuOTByIN88US=> MmnENlQwPzJiaB?= NHHON|hl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> Mn64NlI1QTl2M{e=
BON1 M1qyfGFxd3C2b4Ppd{BCe3O|YYm= M{HUTVAuOTBizszN NUfJbVh5OjRiaB?= MnLhbY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= Ml3DNlI1QTl2M{e=
BON1 NEK1eWhHfW6ldHnvckBCe3OjeR?= M{L3PFcvPS9zMDFOwG0> M{\OSVghcA>? MXLk[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[geIhmKGGwdHmtZZBweHSxdHnjJJBzd3SnaX7zJGJEVDJiYX7kJGJkdC2[TB?= MkGxNlI1QTl2M{e=
Kasumi-1 NF\xdplE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NHnTVHMxNTJyIN88US=> M{G0[lI1NzR6IHi= Mmfs[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy NWLOVGZSOjJ2MEeyNlg>
HL-60 NIjtZWpE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M3jEXFAuOjBizszN MVSyOE81QCCq MX\k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= MVKyNlQxPzJ{OB?=
Kasumi-1 M4jo[WFxd3C2b4Ppd{BCe3O|YYm= NEPrZWQyOCEQvF2= NU[1[|RnOjRiaB?= M3nzXIlv\HWlZYOgZZBweHSxc3nz M1f1OlIzPDB5MkK4
HL-60 M3\pO2Fxd3C2b4Ppd{BCe3O|YYm= NVTIVGVROTBizszN MnjuNlQhcA>? M{Kwc4lv\HWlZYOgZZBweHSxc3nz MX6yNlQxPzJ{OB?=
Kasumi-1 MkC1SpVv[3Srb36gRZN{[Xl? MXGyMlUwPS9zMDFOwG0> NYjsO2NuOjRiaB?= NUfGT496\GWlcnXhd4V{KEGtdDDhcoQheC2Da4SgcIV3\Wy|wrDkc5NmNWSncHXu[IVvfGy7 MoTyNlI1ODd{Mki=
HL-60 NYfNdGhmTnWwY4Tpc44hSXO|YYm= MVeyMlUwPS9zMDFOwG0> MmnINlQhcA>? M2W2UoRm[3KnYYPld{BCc3RiYX7kJJAuSWu2IHzleoVte8LiZH;z[U1l\XCnbnTlcpRtgQ>? M1niW|IzPDB5MkK4
Kasumi-1 M4XSdWZ2dmO2aX;uJGF{e2G7 Ml\xNk42NzVxMUCg{txO M3zSWFI1KGh? MVvpcoR2[2W|IITo[UBxcG:|cHjvdplt[XSrb36gc4YhUk6NMT:yJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy NXzxWG06OjJ2MEeyNlg>
HL-60 NYDXV29QTnWwY4Tpc44hSXO|YYm= MXeyMlUwPS9zMDFOwG0> MWKyOEBp M2rhRolv\HWlZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCMTluxM|IhcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NFPBNVczOjRyN{KyPC=>
K562 NYnNRo5[TnWwY4Tpc44hSXO|YYm= NFPPOWYzOCEQvF2= M3HkU|Q5KGh? M2q1S4lv\HWlZYOgZZV1d3CqYXf5xsA> MmGzNlI1ODd{Mki=
OCUT1 MnTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVuwMlEuOyEQvF2= MnexOUBl MmDJbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M4r4[lIzODlyMkex
K1 M{XTVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWKwMlEuOyEQvF2= M2HqV|Uh\A>? MoPxbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MlK4NlIxQTB{N{G=
OCUT1 NF;TfWRHfW6ldHnvckBCe3OjeR?= NX7POoFCOyEQvH2= MljNNlQhcA>? MkfwZ4F2e2W|IHGg[JJidWG2aXOgbY5kemWjc3WgbY4hTzJxTTDwbIF{\Q>? M2K2dVIzODlyMkex
CaOV3 NXfaOINrS2WubDDWbYFjcWyrdImgRZN{[Xl? MUSxM|UwOTBizszN NUKxbGEyPDhiaB?= M4rjNYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6ncjDjc5Rz\WG2ZXSge4l1cCCyYXPsbZRigGWu MoTZNlE4PzVyNUS=
SKOV3 MlyyR5l1d3SxeHnjbZR6KEG|c3H5 NFK1W202KM7:TR?= MXi0PEBp NYnEb4R1\W6qYX7j[ZMheGGlbHn0ZZhmdCCrbnT1Z4VlKG:4YYLpZY4h[2GwY3XyJINmdGxiZHXheIjDqA>? M13JUVIyPzd3MEW0
A2780 M4ixc2N6fG:2b4jpZ4l1gSCDc4PhfS=> NFfrWGI2KM7:TR?= MWK0PEBp NWDBTolz\W6qYX7j[ZMheGGlbHn0ZZhmdCCrbnT1Z4VlKG:4YYLpZY4h[2GwY3XyJINmdGxiZHXheIjDqA>? M2jLWVIyPzd3MEW0
HT-29  MkDmR5l1d3SxeHnjbZR6KEG|c3H5 NXzQZplCPSEQvF2= NFTCNnc1QCCq MXHlcohidmOnczDwZYNtcXSjeHXsJIlv\HWlZXSgc5ZiemmjbjDjZY5k\XJiY3XscEBl\WG2aNMg MYmyNVc4PTB3NB?=
A498 NGTicodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13PWlAuPDBizszN MVK3NkBp NWHP[FVbcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NWLsUWI1OjF4NESwOVA>
CAKI-1 NWH1T2pPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn64NE01OCEQvF2= NVj0V45CPzJiaB?= MkL4TWM2OH5zMDFOwG0> NV3DZ3lUOjF4NESwOVA>
769-P M1nkbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIe5elUxNTRyIN88US=> M3XBNlczKGh? NYXxSXhPUUN3MI61MVExKM7:TR?= MVGyNVY1PDB3MB?=
786-0 MojYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWiwMVQxKM7:TR?= NYrjenFWPzJiaB?= MmXsTWM2OH53IN88US=> NGHHTYwzOTZ2NEC1NC=>
786-O NVLyeZhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3pNE0zOCEQvF2= Mn;jO|IhcA>? MmCybY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MknoNlE3PDRyNUC=
CAKI-1 MljIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXGNE0zOCEQvF2= NYewOJhMPzJiaB?= MXLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NIG1SoozOTZ2NEC1NC=>
769-P MnHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\Xe4IxNTJyIN88US=> Mk\lO|IhcA>? MVHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NXnRS4xNOjF4NESwOVA>
A498 NGrkc|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnn6NE0zOCEQvF2= NHLIUlY4OiCq Mk\BbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NGP4UXgzOTZ2NEC1NC=>
CWR22RV1 NHvSe|FE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NXLTW4pUOTBizszN Mmi5NlQhcA>? MVrpcoNz\WG|ZYOgd4Vve2m2aY\peJkhd2ZiaIXtZY4hS1eUMkLSWlEh[2WubIOgeI8hemGmaXH0bY9v MWmyNVQ6PjJ5Mx?=
CWR22RV1 NXSyXlJHSXCxcITvd4l{KEG|c4PhfS=> NIfuOZcyOCEQvF2= MkPKNlQhcA>? NEL3VJRmdmijbnPld{Bz[WSrYYTpc44hcW6mdXPl[EBieG:ydH;zbZM> M2rV[lIyPDl4Mkez
CWR22RV1 MnXvSpVv[3Srb36gRZN{[Xl? NYP5bVRuPSEQvF2= MWmyOEBp MlPKdoVlfWOnZDDwbI9{eGixconsZZRqd25ib3[gRYt1KHOrZ37p[olk[W62bIm= NWjpenBxOjF2OU[yO|M>
HepG2  MkP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nEZVUwOTBxMkCvOFAh|ryP MnrRNlQwPDhxN{KgbC=> MVfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M{fRbFIxQDR{NEK1
Bel-7402 NIfXZWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPuSI42NzFyL{KwM|QxKM7:TR?= Ml\pNlQwPDhxN{KgbC=> Mnq0bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NGf0VI4zODh2MkSyOS=>
HepG2  M3H3[GZ2dmO2aX;uJGF{e2G7 MVG1M|ExNzJyIN88US=> M2rpRlI1KGh? M1uzOpJme3WudIOgbY4hfGinIHHjZ5VufWyjdHnvckBw\iClZXzsJI52dWKncjDpckB1cGViR{KvUUBxcGG|ZR?= NX\4eHptOjB6NEK0NlU>
Bel-7402 M3jJV2Z2dmO2aX;uJGF{e2G7 Mkj0OU8yOC9{MDFOwG0> NGG0[VkzPCCq NU\LWoVRemW|dXz0d{BqdiC2aHWgZYNkfW23bHH0bY9vKG:oIHPlcIwhdnWvYnXyJIlvKHSqZTDHNk9OKHCqYYPl NFfYVXIzODh2MkSyOS=>
HepG2  M1q2cmFxd3C2b4Ppd{BCe3O|YYm= NGLRVmY2NzFyL{KwJO69VQ>? MmXsNlQwPDhiaB?= NVK4VY1ScW6mdXPld{BieG:ydH;zbZMh[XRidHjlJIxwdmdvdHnt[UBmgHCxc4Xy[S=> MoDuNlA5PDJ2MkW=
Bel-7402 MXjBdI9xfG:|aYOgRZN{e2G7 NUjBZ3ZCPS9zMD:yNEDPxE1? M3fjWVI1NzR6IHi= M4HxT4lv\HWlZYOgZZBweHSxc3nzJIF1KHSqZTDsc45oNXSrbXWg[Zhxd3O3cnW= MVqyNFg1OjR{NR?=
OAW-42 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUH3NHdXOC12MDFOwG0> NGXXeYc4OsLiaB?= M{XmbGlEPTC-MUCg{txONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MnPxNlA1ODV{OU[=
PA-1  M4DhWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2S4XFAuPDBizszN MoHHO|LDqGh? MVXJR|UxhjJ3IN88UUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NV7jc|N[OjB2MEWyPVY>
SKOV3  MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHR[WtsOC12MDFOwG0> NXX0WFI{PzMEoHi= MkPmTWM2OH5|MDFOwG0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NGnjfmMzODRyNUK5Oi=>
A2780 MlH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\tUoUxNTJyIN88US=> NGWwOWw1QC95MjDo M1rLWGlEPTEEoE5CpFPDqM7:bR?= M2jJblIxPDB3Mkm2
A2780cis  NF7BfmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjDXJJkOC1{MDFOwG0> MW[0PE84OiCq NHW4UmhKSzVywrC9xsA3yqEQvH2= NXfWUmJqOjB2MEWyPVY>
SKW6.4 NEjEd3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXW1Sm9mOi1zMNMg{txO NF\ndI81QMLiaB?= M1\rVIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NWTES3IyOjBzM{C5OlA>
MAVER M2DGPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfmdY5pOi1zMNMg{txO NXH6SJg4PDkEoHi= MXjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MUeyNFE{ODl4MB?=
BJAB NXP3S45qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvMcpUzNTFywrFOwG0> MYO0POKhcA>? NH;yVXpqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M1HUXVIxOTNyOU[w
OCI MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVyyMVExyqEQvF2= MX20POKhcA>? NHi2WnJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M4HoelIxOTNyOU[w
MOLM M3;aV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPrb|gzNTFywrFOwG0> NV\peId[PDkEoHi= NYfHZY5LcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MXKyNFE{ODl4MB?=
HL-60 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWWyMVExyqEQvF2= MWe0POKhcA>? NGfxPVBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MoDYNlAyOzB7NkC=
SKW6.4 NIm1fIpCeG:ydH;zbZMhSXO|c3H5 MnHtNVDDqM7:TR?= M1PjU|I1NzR6IHi= NUC4b|lmcW6mdXPld{BieG:ydH;zbZMhfGmvZT3k[ZBmdmSnboTsfS=> NXzabm4yOjBzM{C5OlA>
MAVER M4Xj[GFxd3C2b4Ppd{BCe3O|YYm= MX6xNOKh|ryP NEnLUXgzPC92ODDo NELvWYhqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nLXTldIVv\GWwdHz5 NGroc4EzODF|MEm2NC=>
BJAB M{\HPGFxd3C2b4Ppd{BCe3O|YYm= NWr1SJhoOTEEoN88US=> NUjHdHptOjRxNEigbC=> MWnpcoR2[2W|IHHwc5B1d3OrczD0bY1mNWSncHXu[IVvfGy7 MmK1NlAyOzB7NkC=
OCI NGTneZZCeG:ydH;zbZMhSXO|c3H5 M1K1UFExyqEQvF2= M2CyZlI1NzR6IHi= NYDhZWJucW6mdXPld{BieG:ydH;zbZMhfGmvZT3k[ZBmdmSnboTsfS=> Ml3DNlAyOzB7NkC=
MOLM M4\vcGFxd3C2b4Ppd{BCe3O|YYm= MkPINVDDqM7:TR?= MXKyOE81QCCq MoPubY5lfWOnczDhdI9xfG:|aYOgeIlu\S2mZYDlcoRmdnSueR?= MYWyNFE{ODl4MB?=
HL-60 MmnFRZBweHSxc3nzJGF{e3OjeR?= MYexNOKh|ryP MU[yOE81QCCq NUD2UIFjcW6mdXPld{BieG:ydH;zbZMhfGmvZT3k[ZBmdmSnboTsfS=> MVmyNFE{ODl4MB?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AKT / AKT / p-S6K1 / S6K1 ; 

PubMed: 25519148     


The effect of perifosine on AKT-mTOR activation in vitro. RMG1 and RMG2 cells were treated with 0, 3, 10, 30 or 50 μM perifosine for 6 h in the presence of 10% FBS. Cells were harvested, and equivalent amounts (30 μg) of protein were subjected to SDS-PAGE and blotted with anti-phospho-AKT (Ser473), anti-AKT, anti-phospho-S6K1 (Thr389), anti-S6K1, or anti-β-actin antibodies.

PARP; 

PubMed: 25519148     


Perifosine induces apoptosis. RMG1 and RMG2 cells were treated with or without 30 μM perifosine for 24 h. Cells were harvested, and the effect of perifosine was evaluated by western blotting

p-mTOR / mTOR / Raptor / Rictor / p-p70S6K / p70S6K / p-4EBP1 / 4EBP1 / c-Myc / Cyclin D1; 

PubMed: 19920197     


The indicated cell lines were treated with the given concentrations of perifosine (PRFS) for 8 h.

p-PDK1 / p-GSK3α/β / p-S6R ; 

PubMed: 17761832     


BCWM.1 cells were cultured with perifosine for 6 hours with doses that ranged from 2 to 20 μM. Whole cell lysates were subjecting to Western blotting using anti–p-Akt ser473, -Akt, –p-PDK1, –p-GSK3α/β, –p-S6R, and α-tubulin antibodies.

25519148 19920197 17761832
Growth inhibition assay
Cell viability; 

PubMed: 28332584     


Cell survival measured by MTT assay and IC50 of perifosine in a panel of eleven human cancer cells.

28332584
In vivo Perifosine combining with temozolomide reduces tumor proliferation (a PDGF-driven gliomagenesis) in vivo. The results indicate that Perifosine is an effective drug in gliomas in which Akt and Ras-Erk 1/2 pathways are frequently activated, and may be new candidate for glima treatment in the clinic. [2] Both oral daily and weekly administration of Perifosine significantly reduce human MM tumor growth and increase survival, compared with control animals treated with PBS vehicle only. [3] Perifosine induces thrombocytosis and leukocytosis and increases myelopoiesis in murine marrow and spleen, whereas it causes apoptosis in myeloma xenografts. [5]

Protocol

Kinase Assay:[3]
- Collapse

Akt kinase assay:

MM.1S cells are cultured in the presence or absence of perifosine (5 μM, 6 hours) and then stimulated with IL-6 (20 ng/mL, 10 minutes). In vitro akt kinase assay is then carried out using the Akt Kinase Assay Kit.
Cell Research:[2]
- Collapse
  • Cell lines: Human glioma cell lines
  • Concentrations: 0, 15, 30 and 45 μM
  • Incubation Time: 48 hours
  • Method: Cells are incubated in the medium with 10% FCS for 48 hours with indicated concentration of Periosine. Cell viability is determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. (Cell Proliferation Kit I; Roche). The absorbance at 590 nm is recorded using the 96-well plate reader.
    (Only for Reference)
Animal Research:[3]
- Collapse
  • Animal Models: MM.1S MM cells are inoculated subcutaneously in the right flank of Beige-nude-xid (BNX) mice (5 to 6 weeks old).
  • Formulation: 0.9% NaCl solution
  • Dosages: 250 mg/kg/wk or 36 mg/kg/d
  • Administration: Oral gavage
    (Only for Reference)

Solubility (25°C)

In vitro Ethanol 15 mg/mL (32.49 mM)
Water 8 mg/mL (17.32 mM)
DMSO Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
water
For best results, use promptly after mixing.
8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 461.66
Formula

C25H52NO4P

CAS No. 157716-52-4
Storage powder
in solvent
Synonyms NSC639966

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01224730 Completed Drug: perifosine Cancer AEterna Zentaris January 24 2012 Phase 1
NCT01049841 Completed Drug: perifosine + temsirolimus Pediatric Solid Tumors Memorial Sloan Kettering Cancer Center|University of Wisconsin Madison|Duke University|NATL COMP CA NETWORK|Pfizer|AEterna Zentaris January 2010 Phase 1
NCT01048580 Completed Drug: Perifosine|Drug: Capecitabine Colon Cancer AEterna Zentaris|SCRI Development Innovations LLC October 2009 Phase 1
NCT00776867 Completed Drug: perifosine Solid Tumors Memorial Sloan Kettering Cancer Center|University of Wisconsin Madison|Duke University|AEterna Zentaris October 2008 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

Related Akt Products

Tags: buy Perifosine (KRX-0401) | Perifosine (KRX-0401) supplier | purchase Perifosine (KRX-0401) | Perifosine (KRX-0401) cost | Perifosine (KRX-0401) manufacturer | order Perifosine (KRX-0401) | Perifosine (KRX-0401) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID